← Leaderboards
Roger J Kurlander
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Transplantation”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Mary M Horowitz · Medical College Of Wisconsin$224,924,548
- Craig B Thompson · Sloan-Kettering Inst Can Research$157,997,949
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Richard L Schilsky · University Of Chicago$117,759,216
- Harold E Varmus · Sloan-Kettering Institute For Cancer Res$82,854,111
Research focus
TransplantationCellsResearch PersonnelMalignant NeoplasmsMonitorT-LymphocyteLaboratoriesUnited States National Institutes Of HealthProtocols DocumentationBaseAllogenicStem CellsResponseEngraftmentHematopoieticStem Cell TransplantTumorInstitutesPlayImmunologic Assay /TestChimerismRecurrenceHuman TissueMolecular
Grant awards (40)
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$0
ZID · FY2015 · CL · contact PI
Quantitation Of Residual Disease In Patients with Cancer$0
ZID · FY2015 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$0
ZID · FY2014 · CL · contact PI
Quantitation Of Residual Disease In Patients with Cancer$0
ZID · FY2014 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Allo-transplantation$0
ZID · FY2012 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$0
ZID · FY2012 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Allo-transplantation$0
ZID · FY2010 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$0
ZID · FY2010 · CL · contact PI
Monitoring Donor T Cell Alloreactivity During Hematopoietic Transplantation$0
ZIA · FY2010 · CL · contact PI
Preparation of Human Dendritic Cells for use in Clinical Vaccine Protocols$0
ZIA · FY2009 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$0
ZID · FY2009 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Allo-transplantation$0
ZID · FY2009 · CL · contact PI
Monitoring Donor T Cell Alloreactivity During Hematopoietic Transplantation$0
ZIA · FY2009 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$29,796
Z01 · FY2008 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Allo-transplantation$23,837
Z01 · FY2008 · CL · contact PI
Monitoring Donor T Cell Alloreactivity During Hematopoietic Transplantation$14,898
Z01 · FY2008 · CL · contact PI
Preparation of Human Dendritic Cells for use in Clinical Vaccine Protocols$14,898
Z01 · FY2008 · CL · contact PI
Preparation of Human Dendritic Cells for use in Clinical Vaccine Protocols$26,000
Z01 · FY2007 · CL · contact PI
Monitoring Donor T Cell Alloreactivity During Hematopoietic Transplantation$26,000
Z01 · FY2007 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells After Transplantation$16,000
Z01 · FY2007 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Allo-transplantation$11,000
Z01 · FY2007 · CL · contact PI
Quantitation Of Residual Tumor In Patients Undergoing Al$0
Z01 · FY2006 · CL · contact PI
Preparation of Human Dendritic Cells for use in Clinical$0
Z01 · FY2006 · CL · contact PI
Quantitating Engraftment Of Donor Hematopoietic Cells Af$0
Z01 · FY2006 · CL · contact PI
Monitoring Donor T Cell Alloreactivity During Hematopoie$0
Z01 · FY2006 · CL · contact PI
Donor T Cell Alloreactivity During Transplantation$0
Z01 · FY2005 · CL
Quantitating Engraftment Of Donor Hematopoietic Cells Af$0
Z01 · FY2005 · CL
Quantitating Engraftment Of Donor Hematopoietic Cells$0
Z01 · FY2005 · CL
Quantitation Of Residual Tumor In Patients$0
Z01 · FY2005 · CL
Monitoring Donor T Cell Alloreactivity During Hematopoie$0
Z01 · FY2004 · CL
Quantitating Engraftment Of Donor Hematopoietic Cells Af$0
Z01 · FY2004 · CL
Quantitation Of Residual Tumor In Patients Undergoing Al$0
Z01 · FY2004 · CL
Monitoring Donor T Cell Alloreactivity During Hematopoie$0
Z01 · FY2003 · CL
Quantitating Engraftment Of Donor Hematopoietic Cells Af$0
Z01 · FY2003 · CL
Quantitation Of Residual Tumor In Patients Undergoing Al$0
Z01 · FY2003 · CL
T Cell Alloreactivity During Hematopoietic Transplantat$0
Z01 · FY2002 · CL
Quantitating Engraftment Of Donor Hematopoietic Cells$0
Z01 · FY2002 · CL
Residual Tumor In Patients Undergoing Allo-transplant$0
Z01 · FY2002 · CL
Alternative Pathway For Class I Mhc Peptide Presentation$0
Z01 · FY2001 · CL
Evaluation of an Alternative Pathway for Class I MHC Product-dependent Presentat$0
Z01 · FY2000 · CL